All articles tagged with #asco
At the ASCO cancer conference, groundbreaking research revealed that personalized exercise routines can outperform chemotherapy in preventing colon cancer recurrence, and AstraZeneca showcased promising early-stage immunotherapy treatments that could revolutionize cancer care by boosting survival rates and reducing side effects.
At ASCO Day 3, AstraZeneca showcased its dominance, Takeda revealed data on an experimental drug, and Eli Lilly served a salad at its booth, highlighting the event's mix of scientific updates and marketing strategies.
The article provides updates from the ASCO conference, highlighting paradoxes in cancer research, advancements in breast cancer drugs, and recent news involving Gilead and Pfizer, with insights from experts in the field.
Studies presented at the American Society of Clinical Oncology conference in Chicago show that scaling back treatment for ovarian, esophageal, and Hodgkin lymphoma cancers can improve patients' quality of life without compromising outcomes. The research indicates that less surgery, chemotherapy, or radiation can be just as effective, thanks to advancements in cancer drugs and treatment methods.
The week ahead will see a light calendar for major economic releases, with updates on factory orders, consumer credit, and initial jobless claims likely to be the most notable data points. The earnings calendar will feature a few intriguing names like Campbell Soup, DocuSign, and NIO. Meanwhile, the tech sector will be tuned into Apple's WWDC event that could feature an augmented reality headset, new MacBooks, and a first readout from the Cupertino company on how it views the role of AI in the Apple ecosystem. The Chinese electric vehicle maker NIO will report earnings on June 9 with analysts forecasting revenue of $1.68B and EPS of -$0.32 to be disclosed. One of the biggest healthcare conferences of the year, the American Society of Clinical Oncology, will run during the week. Cisco will hold its four-day Cisco Live! IT event in Las Vegas. Steris was singled out this week as an appealing stock pick.